Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
View original at finance.yahoo.comLilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment Analyses across Kisunla (donanemab-azbt) trials providing further insights into the benefit-risk profile from long-term extension data New data compares the d…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The external controls versus internal extrapolation analysis addresses a key methodological question in Alzheimer's disease research: how long-term outcomes are measured and interpreted in clinical trials, reflecting Lilly's commitment to the scientific rigor that underpins credible long-term evidence generation.
60% confidenceP-tau217 blood biomarker assays demonstrated strong rule-in performance comparable to amyloid PET for identifying Alzheimer's disease pathology in cognitively unimpaired individuals.
60% confidenceThough blood biomarker tests and amyloid PET agents are not currently indicated for use in cognitively unimpaired individuals, the results generate support for a potentially scalable, accessible alternative to specialized imaging in the future.
60% confidenceResearch spanning diagnostics, long-term treatment, disease biology, and patient-centered outcomes reflects Lilly's 35-year commitment to Alzheimer's disease science.
60% confidence
Data points we hold from this source
| Eli Lilly and Company · poster presentations | 13 count |